SPOTLIGHT -
Our Launch-Time Menu
In this September 2020 Product Launch issue of Pharm Exec, we highlight five products, all approved in 2019, and showcase what is now their early brand journey.
Drug Launch: Winning the Evidence Battle
Beyond necessity and nice-to-have, embracing real-world evidence as a true strategic differentiator.
COVID Causes Pharma Marketers to Watch TV
Succession Plan: Skyrizi
Turning to a next-gen psoriasis treatment to help drive future fortunes.
New Standards for First-to-Launch Players
While COVID-19 has shifted some of the rules, research reveals that practice changes were already afoot for market newcomers.
(O)mega Opportunity: Vascepa
Uncovering fish oil derivative’s benefit for heart health.
Educational Mission: Oxbryta
New hope accompanies overdue recognition in sickle cell disease fight.
First in Class: Spravato
Addressing the need for fast-acting therapy in treatment-resistant depression.
One Time for Lifetime: Zolgensma
The world’s most expensive drug put in context.
Biopharma Capital Markets Sizzle in 2020
The key factors behind the sector’s strong surge in new equity fundraisings.
Key Support for Rare Disease Medicine Scheme
Orphan drug incentives set to remain in place in Europe.
FDA in Hot Seat on ‘Buy American’ Drug Policy
Tasked with setting up framework for essential medicine program.
Unlocked Potential — ‘Keying’ in On New-Era Engagement
How adoption of the key account management (KAM) model can help drive pharma’s agility in reaching and influencing a more diverse set of healthcare customers and decision-makers.
Vaccine Supply: Trusting in Blockchain
As we wait for a COVID-19 vaccine, pharma is looking to blockchain technology to prepare for the major supply-chain obstacles to come.
The Importance of Embracing Diversity
Creating behavioral change in the pharma workplace.
Staying the Course in Product Launch
Amid pandemic, rely on the fundamentals.
Stepping Out in Oncology
A glimpse inside the latest turn in Liz Barrett’s influential journey as an oncology executive—this time leaving the confines of big pharma to tackle the innovation void in treating urologic cancers.
Sustainable Long-Term Planning
ESG objectives are integral to long-term biopharma strategy.
Taking Biopharma’s Pulse in a Tough 2020
Assessing COVID-19’s wide and varied impact on pharma and biotech business in the first half of the year, and how it shapes market prospects ahead.
Pharmaceutical Executive, September 2020 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive September 2020 issue in an interactive PDF format.